Patents Assigned to Millennium Pharmaceuticals, Inc.
  • Substituted hydroxamic acids and uses thereof
    Patent number: 9096518
    Abstract: This invention provides compounds of formula (I) wherein R1, R2, G, m, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: August 4, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Jeffrey P. Ciavarri, Kenneth M. Gigstad, He Xu
  • Thiazole derivatives
    Patent number: 9090601
    Abstract: The present invention relates to a compound represented by the formula (I) or (I?): wherein each symbol is as defined in the specification, or a salt thereof, and a PI3K and(or) mTOR inhibitor containing the compound or a prodrug thereof.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: July 28, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Hiroshi Banno, Masaaki Hirose, Osamu Kurasawa
  • Molecules of the card-related protein family and uses thereof
    Patent number: 9085639
    Abstract: Novel CARD-9, CARD-10, or CARD-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated CARD-9, CARD-10, or CARD-11 proteins, the invention further provides CARD-9, CARD-10, or CARD-11, fusion proteins, antigenic peptides and anti-CARD-9, CARD-10, or CARD-11 antibodies. The invention also provides CARD-9, CARD-10, or CARD-11 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CARD-9, CARD-10, or CARD-11 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: July 21, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: John Bertin
  • BIOMARKERS OF RESPONSE TO PROTEASOME INHIBITORS
    Publication number: 20150184246
    Abstract: Disclosed herein are markers associated with sensitivity to treatment with proteasome inhibitors. Sensitivity is observed when RAS gene is wild type in tumor cells.
    Type: Application
    Filed: November 9, 2012
    Publication date: July 2, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Allison Berger, Hughes Bernard, Nibedita Chattopadhyay, Erik M. Koenig, George J. Mulligan, Matthew J. Schu
  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20150183753
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: September 8, 2014
    Publication date: July 2, 2015
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Courtney Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead
  • Heteroaryls and uses thereof
    Patent number: 9062038
    Abstract: This invention provides compounds of formula IA or IB: wherein HY, R1, R2, G1, W, n, and A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: June 23, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Masaaki Hirose, Yongbo Hu, Zhigen Hu, Hong Myung Lee, Zhan Shi, Stepan Vyskocil, Tianlin Xu
  • Pharmaceutical salts and polymorphs of a factor Xa inhibitor
    Patent number: 9061019
    Abstract: The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: June 23, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Craig Grant, James P. Kanter, Graeme Langlands
  • CCR9 inhibitors and methods of use thereof
    Patent number: 9035096
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: May 19, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Geraldine C. B. Harriman, Zhan Shi, B. Shaowu Chen
  • Thiophenes and uses thereof
    Patent number: 9029411
    Abstract: This invention provides thiophene compounds of formula I: wherein R1, R2, R3, R4, n, p, and m are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: May 12, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christelle C. Renou, Tricia J. Vos, Matthew O. Duffey, Robert Downham
  • Derivatives of 1-amino-2-cyclopropylethylboronic acid
    Patent number: 9023832
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: May 5, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Jing Li
  • BIOMARKERS OF RESPONSE TO NAE INHIBITORS
    Publication number: 20150119410
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Application
    Filed: October 26, 2012
    Publication date: April 30, 2015
    Applicants: Millennium Pharmaceuticals, Inc, Massachusetts General Hospital
    Inventors: Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Llightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman
  • PREPARATION OF AMINOTETRALIN COMPOUNDS
    Publication number: 20150112071
    Abstract: The present invention relates to synthetic processes for preparation of aminotetralin compounds with kinase inhibitory activity. The invention also provides synthetic intermediates useful in the processes of the invention.
    Type: Application
    Filed: May 29, 2014
    Publication date: April 23, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Alexandra E. Gould, Sean J. Harrison, Hirotake Mizutani, Ming Shen, Thomas E. Smyser, Stephen G. Stroud
  • BIOMARKERS OF RESPONSE TO NAE INHIBITORS
    Publication number: 20150105411
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Application
    Filed: October 26, 2012
    Publication date: April 16, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Stephen J. Blakemore, Bin Li, George J. Mulligan, Matthew C. Schu, Peter G. Smith
  • Anti-GCC antibody molecules and methods for use of same
    Patent number: 9000129
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Grant
    Filed: April 27, 2013
    Date of Patent: April 7, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Helen Alison Frank, Alice A. McDonald, Theresa L. O'Keefe
  • Methods of synthesizing factor Xa inhibitors
    Patent number: 8987463
    Abstract: Described herein are novel methods of preparing a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the method is for preparing betrixaban or a pharmaceutically acceptable salt thereof. Also described are compositions comprising substantially pure betrixaban free base or salt thereof.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: March 24, 2015
    Assignees: Millennium Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc.
    Inventors: Anjali Pandey, Emilia P. T. Leitao, Jose Rato, Zhiguo Jake Song
  • PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS
    Publication number: 20150080573
    Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((1S,2S,4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 19, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
  • Administration of a NEDD8-activating enzyme inhibitor and hypomethylating agent
    Patent number: 8980850
    Abstract: The present disclosure relates to methods for the treatment of cancer in patients in recognized need of such treatment. The methods comprise administering to such a patient an NAE inhibitor or a pharmaceutically acceptable salt thereof, such as ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216), and a hypomethylating agent or a pharmaceutically acceptable salt thereof, such as azacitidine or decitabine. Also disclosed are medicaments for use in the treatment of cancer.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: March 17, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Peter G. Smith
  • BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES
    Publication number: 20150072942
    Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
    Type: Application
    Filed: April 8, 2014
    Publication date: March 12, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yu-Ting Ma, Ross L. Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
  • Substituted hydroxamic acids and uses thereof
    Patent number: 8952163
    Abstract: This invention provides compounds of formula (I): wherein R1a, R1b, R1c, R1d, R2a, R2b, X1, X2, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: February 10, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Kenneth M. Gigstad, He Xu
  • SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS
    Publication number: 20150038706
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Application
    Filed: March 6, 2014
    Publication date: February 5, 2015